Old Web
English
Sign In
Acemap
>
Paper
>
Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML
Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML
2021
Tomasz Rzymski
Urszula Pakulska
Camille N. Abboud
Howard A. Burris
Scott R. Solomon
Marta Obacz
Kristina Goller
Michał Combik
Jan Maciej Zaucha
Milena Mazan
Michal Mikula
Magdalena Cybulska
Anna Polak
Przemyslaw Juszczynski
Marcus Järås
Marion Chapellier
Johan Flygare
Magdalena Zawadzka
Karolina Bukowska-Strakova
Krzysztof Brzózka
Setareh Shamsili
Noemi Angelosanto
Keywords:
Cancer research
Cyclin-dependent kinase 8
Medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]